Background:
Large bone defects and infections still represent a major challenge to orthopedic surgeons. Bone infection is a very serious condition resulting in patient suffering, financial burden, and sometimes fatalities. The main cause for bone infection is usually trauma, diabetes and biomaterial-related implant associated infections. Infection is a significant cause for implant failure, impaired functionality, and reduced lifetime of medical devices, resulting in high distress for the patients and large socioeconomic costs [4-7]. It would be of a great advantage to use tissue engineered bone grafts that could control infection, while promoting bone regeneration avoiding multiple surgeries and delaying reconstruction. While local use of antibiotics is currently the most common treatment for bone graft infections, the extensive use of antibiotics worldwide during the last decades has led to antimicrobial resistance …show more content…
Methicillin-resistant Staphylococcus aureus (MRSA) is a well-known example of a bacterium that is resistant to a number of antibiotics and is the main cause of hospital-acquired infections (HAI) all across the EU. EU funds are already spent in several interventions aimed at improving knowledge and promoting research on AMR. Research on AMR has been financially supported by the Commission services under the EU’s Seventh Framework Programme for Research and Technological Development. The new EU framework programme Horizon 2020 continues to give research on infectious diseases including AMR a high priority. The European Commission has also joined forces with SMEs and large pharmaceutical industries to spur the development of new antibiotics, which led to new EU funded research projects
Large bone defects and infections still represent a major challenge to orthopedic surgeons. Bone infection is a very serious condition resulting in patient suffering, financial burden, and sometimes fatalities. The main cause for bone infection is usually trauma, diabetes and biomaterial-related implant associated infections. Infection is a significant cause for implant failure, impaired functionality, and reduced lifetime of medical devices, resulting in high distress for the patients and large socioeconomic costs [4-7]. It would be of a great advantage to use tissue engineered bone grafts that could control infection, while promoting bone regeneration avoiding multiple surgeries and delaying reconstruction. While local use of antibiotics is currently the most common treatment for bone graft infections, the extensive use of antibiotics worldwide during the last decades has led to antimicrobial resistance …show more content…
Methicillin-resistant Staphylococcus aureus (MRSA) is a well-known example of a bacterium that is resistant to a number of antibiotics and is the main cause of hospital-acquired infections (HAI) all across the EU. EU funds are already spent in several interventions aimed at improving knowledge and promoting research on AMR. Research on AMR has been financially supported by the Commission services under the EU’s Seventh Framework Programme for Research and Technological Development. The new EU framework programme Horizon 2020 continues to give research on infectious diseases including AMR a high priority. The European Commission has also joined forces with SMEs and large pharmaceutical industries to spur the development of new antibiotics, which led to new EU funded research projects